Therapeutic targeting of MLL.
Treatment of hematologic malignancies is evolving from a uniform approach to targeted therapies directed at the underlying molecular abnormalities of disease. The mixed lineage leukemia (MLL) proto-oncogene is a recurrent site of genetic rearrangements in acute leukemias; and since its discovery in 1992, many advances have been made in understanding its role in leukemogenesis. A variety of MLL translocation partners have been described, and detailed structure/function studies have identified functional domains that are required for transformation. Proteins associated with the MLL core complex or its fusion partners have been isolated and characterized for their critical roles in leukemia pathogenesis. Downstream mediators of MLL transcriptional regulation and multiple collaborating signaling pathways have been described and characterized. These advances in our understanding of MLL-related leukemogenesis provide a foundation for ongoing and future efforts to develop novel therapeutic strategies that will hopefully result in better treatment outcomes.
Liedtke
Michaela
M
Department of Pathology, Stanford University School of Medicine, Stanford, CA 94305, USA. mliedtke@stanford.edu
Cleary
Michael L
ML
D011495:Histone-Lysine N-Methyltransferase; D006801:Humans; D007938:Leukemia / Q000378:metabolism / Q000628:therapy*; D051788:Myeloid-Lymphoid Leukemia Protein / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism*; D000090063:Proto-Oncogene Mas
C497422:KMT2A protein, human; C000715470:MAS1 protein, human; D000090063:Proto-Oncogene Mas; D051788:Myeloid-Lymphoid Leukemia Protein; D011495:Histone-Lysine N-Methyltransferase